医药导报2025，Vol.44Issue(10)：1566-1572,7.DOI:10.3870/j.issn.1004-0781.2025.10.007
抗体偶联药物致重度骨髓抑制患者的药学监护
Pharmacological Monitoring of Patients with Severe Myelosuppression Caused by Antibody-drug Conjugate
摘要
Abstract
Objective To explore the role of clinical pharmacists in the treatment of advanced breast cancer patients with severe myelosuppression.Methods This case report describes the diagnostic and therapeutic process of an advanced breast cancer patient who developed severe myelosuppression after applying ADC-based drug therapy.The clinical pharmacist proposed a prophylactic antimicrobial drug selection plan and medication monitoring recommendations for the patient's granulocytopenic fever after assessing the risk of infection and liver and renal function.For oncology drug-associated thrombocytopenia,when the doctor proposed to use the recombinant human thrombopoietin combined with TPO agonists in the case of the ineffectiveness of conventional treatment,the clinical pharmacist searched for the pharmacological basis of the combination regimen,the clinical studies of the efficacy and the adverse reactions to assist the physician's decision-making and provided targeted medication monitoring of the patient.Results The clinician and clinical pharmacist developed and implemented a rational treatment plan,and the patient was discharged with improvement.Conclusions Clinical pharmacists can assist physicians in optimizing individualized treatment plans through pharmacological monitoring of advanced breast cancer patients with severe myelosuppression.This collaborative treatment model can provide patients with more individualized treatment;it can also provide clinical reference to the treatments of patients with severe myelosuppression.关键词
抗体偶联药物/骨髓抑制/临床药师/药学监护Key words
Antibody drug conjugate/Myelosuppression/Clinical pharmacist/Pharmacologic monitoring分类
医药卫生引用本文复制引用
李鹏远,史蕤,刘笑然,冉然..抗体偶联药物致重度骨髓抑制患者的药学监护[J].医药导报,2025,44(10):1566-1572,7.基金项目
北京市自然科学基金资助项目(7212011). （7212011）
